Factors | LNM group (N = 88) | non-LNM group (N = 287) | X2, Z or t value | P |
---|---|---|---|---|
Sex | 3.98 | 0.04* | ||
Male | 49 | 125 | ||
Female | 39 | 162 | ||
Hashimoto's thyroiditis | 4.87 | 0.03* | ||
No | 67 | 247 | ||
Yes | 21 | 40 | ||
Microcalcifications | 0.29 | 0.58 | ||
No | 64 | 217 | ||
Yes | 24 | 70 | ||
Tumour aspect ratio | 1.56 | 0.21 | ||
1 (< 1) | 63 | 224 | ||
2 (> 1) | 25 | 63 | ||
Tumour location | 1.39 | 0.16 | ||
1 (Upper lobe) | 38 | 144 | ||
2 (Middle lobe) | 17 | 58 | ||
3 (Inferior lobe) | 33 | 85 | ||
Tumour adjacency to the thyroid capsule | 3.33 | < 0.05* | ||
1 (away from the capsule) | 44 | 203 | ||
2 (closely adherent to the capsule) | 32 | 61 | ||
3 (penetrated the capsule) | 12 | 23 | ||
Pathological subtype | 4.72 | < 0.05* | ||
3 (papillary carcinoma) | 41 | 199 | ||
2 (follicular carcinoma) | 32 | 75 | ||
1 (medullary and anaplastic carcinoma) | 15 | 13 | ||
Grading of tumour ultrasound elastography | 1.75 | 0.08 | ||
1 | 42 | 165 | ||
2 | 17 | 61 | ||
3 | 21 | 36 | ||
4 | 4 | 16 | ||
5 | 4 | 9 | ||
Hypertension history | 8.73 ± 7.26 | 13.31(0,11.13) | 0.47 | 0.63 |
Diabetes history | 3.31(0,6.23) | 3.00(0,7.01) | 0.52 | 0.61 |
Smoking history | 8.78 ± 7.21 | 8.13 ± 6.89 | 0.76 | 0.45 |
Drinking history | 9.98 ± 8.92 | 8.66 ± 8.77 | 1.23 | 0.22 |
Tumour diameter | 11.37 ± 1.56 | 11.21 ± 1.64 | 0.84 | 0.39 |
BMI | 22.70 ± 2.61 | 22.45 ± 2.62 | 0.79 | 0.42 |
Triiodothyronine (T3) level | 1.26 ± 0.31 | 1.32 ± 0.35 | 1.49 | 0.14 |
Thyroxine(T4) level | 9.38 ± 2.78 | 9.64 ± 2.91 | 0.75 | 0.45 |
Thyroid-stimulating hormone (TSH) level | 3.75 ± 1.57 | 3.90 ± 1.68 | 0.73 | 0.46 |
Plain CT value | 50.03 ± 10.16 | 54.90 ± 12.55 | 1.27 | 0.21 |
Arterial phase CT value | 108.44 ± 20.67 | 103.60(86.70,114.31) | 1.77 | 0.08 |
Venous phase CT value | 102.63 ± 19.92 | 103.60(83.70,112.40) | 1.81 | 0.07 |
Age | 46.51 ± 7.62 | 46.04 ± 6.58 | 0.56 | 0.57 |
Delta Radscore | 0.32 ± 0.08 | 0.21 ± 0.09 | 9.62 | < 0.05* |
Radscore 1 | 0.32 ± 0.09 | 0.21 ± 0.11 | 8.53 | < 0.05* |